Giugno 2019 - Volume XXXVIII - numero 6
Farmacoriflessioni
UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna
Indirizzo per corrispondenza: federico.marchetti@auslromagna.it
Key words: Domperidone, Italian Medicines Agency, Anti-emetics
On 2nd May 2019 the Italian Medicines Agency (AIFA) issued an “Informative Note agreed upon with the European Regulatory Authorities” on domperidone entitled Memorandum on recommendations for minimising heart risks and eliminating prescriptions in Paediatrics. The note was drafted in collaboration with the authorised pharmaceutical companies that produce this drug. The present article reports the full note (because of its informative nature) and comments its case that has been lasting for many years making physicians think about the use of anti-emetics in Paediatrics both from a methodological and practical perspective.
Vuoi citare questo contributo?